The American Association for Cancer Research (AACR) Annual Meeting is one of the largest and most influential academic events in the global oncology field. The 2026 AACR Annual Meeting will be held in San Diego, USA, from April 17 to 22, 2026.

Currently, the AACR Annual Meeting has become an important platform for domestic innovative pharmaceutical companies to showcase their latest research results. At this year's meeting, more than 100 Chinese pharmaceutical companies participated, presenting nearly 400 research results covering cutting-edge fields such as ADCs, bispecific antibodies, multi-antibodies, mRNA, and AI-driven drug development.

Biocytogen will showcase 36 of its latest research findings in poster format, including various drug forms such as fully human monoclonal antibodies, bi/multispecific antibodies, monoclonal and bispecific antibody-drug conjugates (ADCs), nanobodies (VHHs), and TCR molecules, as well as 12 advances in preclinical animal models and pharmacological and efficacy studies.

Veolia Biotech will announce the latest research results from two preclinical pipelines, showcasing the technological strength of its IO+ADC synergistic platform. Specifically, this includes preclinical research data on the world's first T-cell connector-drug conjugate (TDC) LBL-054 and the novel EGFR/PD-L1 bispecific antibody ADC drug LBL-061.

Orange Sail Pharmaceuticals will showcase three innovative drugs at this conference: VBC101 (EGFR/cMET bispecific antibody ADC) in the clinical stage, and VBC229 (DLL3 bispecific TCE-TOPO1i fusion molecule) and VTS208 (CD3/CLDN18.2/CDH17 trispecific TCE) in the preclinical stage.

Junshi Biosciences will release data for the first time from a Phase I first-in-human (FIH) clinical trial of JS212 (EGFR/HER3 bispecific antibody ADC) for advanced solid tumors and a preclinical study, as well as data from two Phase II clinical trials of JS207 (PD-1/VEGF bispecific antibody) in combination with chemotherapy for metastatic colorectal cancer (CRC) and JS207 (CTLA-4 monoclonal antibody) in combination with JS007 for advanced hepatocellular carcinoma (HCC).

Everest Medicines will announce the first-in-human trial data for its self-developed mRNA personalized cancer therapeutic vaccine, EVM16. This drug is a novel mRNA personalized cancer therapeutic vaccine developed by Everest Medicines and driven by AI algorithms to identify tumor neoantigens. Based on each patient's unique tumor cell mutations, the self-developed EVER-NEO-1 "Miaosuan" tumor neoantigen AI algorithm system, with self-iterative capabilities, identifies tumor neoantigens with high immunogenicity and designs mRNA therapeutic vaccines encoding dozens of tumor neoantigens. Preclinical studies have shown that it can effectively activate neoantigen-specific T cells and significantly inhibit tumor growth, while exhibiting good safety and tolerability.

Abogen Biosciences ' CD19/CD3 TCE mRNA lipid nanoparticle ABO2203 has been successfully selected for oral presentation at AACR, where the results of the first human clinical trial of ABO2203 will be announced to evaluate the safety, tolerability and preliminary efficacy of ABO2203 in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).

Insilicon had four preclinical research findings from its independently developed oncology pipeline selected for the conference poster presentation session, including the novel oral pan-KRAS inhibitor ISM6166, the AI-assisted innovative CBLB inhibitor ISM3830, the AI-driven CDK4 selective inhibitor ISM6210, and the MTA synergistic PRMT5 inhibitor ISM1745.

https://news.yaozh.com/archive/47720.html